Dendritic cells are in every person?s bloodstream. Their usual function is to identify a foreign substance, including cancer cells, and process the bits of such foreign substances and then jumpstart the immune response by bringing the foreign substance to the attention of the rest of the immune system (mostly T lymphocyte cells). The activated immune system is then able to circulate throughout the body and destroy the cancer cells.


Theoretically all cancers can be treated, by Dendritic cells. To date, therapeutic benefit has been documented in B cell lymphoma, myeloma, melanoma, head and neck, prostate cancer, colon cancer, ovarian cancer, breast cancer, and renal cell cancer amongst others.


The patient can consider Dendritic cell therapy at any stage of the cancer.


Responses have generally been promising as it is an autologous process; It does not have side effects, reduces cancer morbidity and improves the quality of life. Depending on the type of cancer and the functional status of patients the response may differ from patient to patient


Few ingredients are added like cytokines such as recombinant human Il 4 recombinant human GMC SF and antibiotics to process the preparation of the Formulation.


Multiple early phases of Dendritic Cell therapy for cancer have been completed and establish the treatment as generally safe.


Immunologic testing can better establish the condition of the immune system to help physicians determine if a patient is a good candidate for Dendritic Cell therapy. Active autoimmune disease as well as pregnancy is possible contraindications. Contradictions should be carefully discussed and reviewed with the consulting physician before proceeding.